Toremifene claimed to be useful in prostate cancer

Posted : Mon, 26 Feb 2007 10:41:02 GMT
Author : Anne Roberts
Category : Health
News Alerts by Email ( click here )
Health News | Home
ORLANDO - Biotech group GTX Inc on Friday claimed that its proposed treatment Acapodene has shown that it can mitigate two of the serious side effects that are caused by undergoing prostate cancer therapy ADT.

The company revealed that the results of its Phase III clinical trial has shown clearly that Acapodene, also known as toremifene, reduces two of the most serious side effects of androgen deprivation therapy, or ADT. These side effects include decrease in bone density and increase of certain fats, such as cholesterol and triglycerides, in the blood, which can cause cardiovascular disease and diabetes.

The Phase III data were revealed on Friday by Dr. Matthew Smith, an oncologist at the Massachusetts General Hospital Cancer Center, at the American Society for Clinical Oncology's annual prostate cancer symposium. In a statement, Dr Smith said, "In previous studies, other agents, including bisphosphonates, have also been associated with significant improvements in bone mineral density in men receiving androgen deprivation therapy for prostate cancer."

Dr Smith added that toremifene can also keep the lipid levels in the balance. "However, these results suggest that toremifene has the potential not only to reduce the risk of fractures in men with advanced prostate cancer, but also to improve lipid levels, addressing another significant side effect of the standard treatment for this disease", he said.

Meanwhile speaking to Market Watch, GTX Chief Executive Officer Dr. Mitchell Steiner has said that the company will be filing for U.S. regulatory approval as soon as the final study is completed some time in the first half of 2008.

Steiner added that the company's other research study, where it is looking to develop a drug to prevent prostate cancer in men who show signs of harboring precancerous lesions, will be completed by the first quarter of 2008.

Copyright, respective author or news agency

Share/Save/Bookmark

Article : Toremifene claimed to be useful in prostate cancer
Print this article
Email this article

Stay Updated
News gadget on your Google homepage
Subscribe to a news feed in Google Reader



Have your Say
Name
Email
Subject
Your Comment

Enter Verification code
 
  

 

 

More Health News click here
Follow The Earth Times
Subscribe to RSS Follow Earth Times on TwitterNews by email
Share/Save/Bookmark

 
 



 
Subscribe to free Earthtimes
News Alerts by Email Click here
For RSS Feeds Click here
or Create your own RSS

Add to Google Toolbar
Breaking News
Press Releases


The Earth Times
News Category

© 2009 www.earthtimes.org, The Earth Times, All Rights Reserved | Privacy Policy
Earth Times accept no responsibility or liability either directly or indirectly for views or opinions expressed in articles or comments.